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ABSTRACT
Introduction: Rheumatic heart disease (RHD) remains
a major contributor to morbidity and mortality in
developing countries. The reported prevalence rates of
RHD are highly variable and mainly attributable to
differences in the sensitivity of either clinical
screening to detect advanced heart disease or
echocardiographic evaluation where disease is
diagnosed earlier across a continuous spectrum. The
clinical signiﬁcance of diagnosis of subclinical RHD by
echocardiographic screening and early implementation
of secondary prevention has not been clearly
established.
Methods and analysis: The authors designed
a cross-sectional survey to determine the prevalence
of RHD in children from private and public schools
between the age of 5 and 15 years in urban and rural
areas of Eastern Nepal using both cardiac auscultation
and echocardiographic evaluation. Children with RHD
will be treated with secondary prevention and enrolled
in a prospective cohort study. The authors will
compare the prevalence rates by cardiac auscultation
and echocardiography, determine risk factors
associated with diagnosis and progression of RHD,
investigate social and economic barriers for
receiving adequate cardiac care and assess clinical
outcomes with regular medical surveillance as
a function of stage of disease at the time of
diagnosis. Prospective clinical studies investigating the
impact of secondary prevention for subclinical RHD on
long-term clinical outcome will be of central relevance
for future health resource utilisation in developing
countries.
Ethics and dissemination: The study was
considered ethically uncritical and was given an
exempt status by the ethics committee at University of
Bern, Switzerland. The study has been submitted to the
National Nepal Health Research Council and was
registered with http://www.ClinicalTrials.gov
(NCT01550068). The study ﬁndings will be reported in
peer-reviewed publications.
ClinicalTrials.gov Identiﬁer: NCT01550068.
INTRODUCTION
Rheumatic fever complicated by rheumatic
heart disease (RHD) remains a major
contributor to morbidity and premature
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ARTICLE SUMMARY
Article focus
- Study protocol of a population-based evaluation
of the prevalence rate of RHD among school-
children in Eastern Nepal, with a subsequent
prospective longitudinal cohort study assessing
long-term clinical outcome of children under-
going secondary prevention for borderline and
deﬁnite RHD according to the World Heart
Federation criteria.
Key messages
- RHD remains a major contributor to morbidity
and mortality in developing countries.
- Echocardiographic screening allows diagnosis of
RHD at an earlier stage across a continuous
spectrum as compared with cardiac auscultation.
- The clinical signiﬁcance of diagnosis of subclin-
ical RHD by echocardiographic screening and
early implementation of secondary prevention
has not been clearly established.
Strengths and limitations of this study
- The protocol describes a comprehensive
approach to implement echocardiographic
screening in a high prevalence region as
recommended by the WHO and outlines
a robust analysis plan to investigate clinical
outcome with secondary prevention for subclin-
ical RHD.
- Since access to education is a marker of
socioeconomic status, restriction of screening
to school going children is subjected to selection
bias likely to underestimate the real disease
burden related to RHD in Eastern Nepal.
- Cultural sensitivity with education programmes
and focus group discussions will anticipate the
potential social stigma of a diagnosis with a heart
condition during childhood and increase public
awareness.
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1 RHD
results from an autoimmune response due to molecular
mimicry between the M-protein on the group A b-
haemolytic streptococci cell membrane and cardiac
myosin eventually leading to valvular damage.
2 High
prevalence rates of acute rheumatic fever (ARF) and
RHD have been reported from different geographic
regions around the world such as Southeast Asia, the
Western Paciﬁc and Africa that share demographic
characteristics determined by poverty and limited access
to healthcare resources.
3 The burden of RHD is likely to
escalate in these countries due to increasing urbanisa-
tion and overcrowding.
Prevalence rates of RHD from screening studies in
Southeast Asian countries range from 0.7 to 22 per 1000
children using traditional cardiac auscultation and from
20 to 51 per 1000 children using echocardiography.
4e11
A considerable variation in prevalence rates reﬂects the
substantially higher sensitivity of echocardiographic
screening as compared with cardiac auscultation due to
diagnosis across a continuous spectrum of disease as
opposed to presence or absence of a heart murmur
using cardiac auscultation. Echocardiographic screening
for RHD has been recommended by the WHO in high
prevalence regions,
12 and the recently released criteria
for echocardiographic diagnosis of RHD by the World
Heart Federation warrant consistent reporting and
facilitate the evaluation of progression of minor echo-
cardiographic lesions over time.
13 The diagnosis of RHD
at an earlier clinically silent stage by the detection of
morphological and functional valvular lesions without
a corresponding heart murmur challenges our current
concept of prevention and treatment.
Medical management of ARF and RHD largely
depends upon preventive measures comprising reduc-
tion of overcrowding, prompt antibiotic treatment of
streptococcal pharyngitis and secondary prevention
achieved by regular oral or intramuscular administration
of penicillin continued until early adulthood among
children with a documented history of ARF or evidence
of RHD. Even though preventive measures with peni-
cillin are inexpensive and efﬁcient, this strategy is difﬁ-
cult to effectuate in developing countries with limited
access to healthcare resources. Enrolment of patients
with ARF and RHD in a registry with close follow-up has
been demonstrated to reduce the cardiovascular
sequelae associated with disease progression.
14
Effective measures to reduce the global burden of RHD
represent an ongoing challenge involving reduction in
overcrowding, improving hygiene, increasing public
awareness and facilitating access to healthcare. In the
absence of fundamental socioeconomic changes
improving primordial prevention, systematic screening for
RHD based on public and private education represents
the most comprehensive approach and aims at a reduc-
tion of the late complications of RHD by early imple-
mentation of secondary prevention. Current research has
been predominantly focused on assessing prevalence rates
using passive survey systems without subsequent enrol-
ment in registries or offering longitudinal follow-up. In
order to assess the determinants of disease and its
progression along with short- and long-term clinical
outcomes, we plan to include all cases of RHD in a cohort
study to be treated according to their disease stage at
diagnosis and followed up for at least 5 years.
AIMS AND OBJECTIVES
The objective of this study is to investigate the preva-
lence rate of deﬁnite and borderline RHD among chil-
dren in Eastern Nepal and to assess long-term clinical
outcome of children undergoing secondary antibiotic
prevention for RHD. More speciﬁcally, we aim to (a)
compare the prevalence rates by cardiac auscultation
and echocardiography, (b) determine risk factors asso-
ciated with diagnosis and progression of RHD, (c)
investigate social and economic barriers for receiving
adequate cardiac care and (d) assess clinical outcomes as
a function of stage of disease at the time of diagnosis
with regular medical surveillance.
METHODS
Study design and setting
A cross-sectional survey of schoolchildren in the Sunsari
district of Eastern Nepal will be performed to identify
children with RHD, and those with evidence of disease
will subsequently be enrolled in a prospective longitu-
dinal cohort study for a period of 5 years. The Sunsari
district situated on the foothills of the Lower Himalayan
Range in Eastern Nepal involves 52 villages with a total
population of around 630000 inhabitants. Dharan is the
largest city in the Sunsari district and the third largest
city in the country.
Cross-sectional survey
We will perform clinical and echocardiographic screening
of children aged 5e15 years from public and private
schools in urban and rural areas in Eastern Nepal. A
multistage sampling procedure will be used to select the
study sample. In order to ensure a representative target
population, the location and administration of the schools
will be used as a surrogate to reﬂect the socioeconomic
demographic distribution of the population in Eastern
Nepal. Since approximately 80% of the population in
Nepal lives in rural areas,
15 we will include three rural and
one urban area in Eastern Nepal and enrol one-third of
the patients from the urban area from private schools.
Prospective cohort study
All children with documented history of ARF and/or
echocardiographic evidence of RHD will be reexamined
in regular time intervals, at 6 months, at 1 year and yearly
thereafter up to at least 5 years, in the context of
a prospective cohort study. Both children and their
primary care givers will be educated in order to ensure
compliance with secondary prevention and regular
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ical symptoms, compliance to treatment and assess
prespeciﬁed clinical end points. Echocardiographic
follow-up will be performed yearly up to 5 years at B.P.
Koirala Institute of Health Sciences (BPKIHS).
Study population
For the cross-sectional survey, all parents of the school-
children will be informed by a letter distributed to the
children outlining the project details and indicating
a contact address for queries. Since close to half of the
adult population in Nepal is illiterate,
15 focus group
discussions with the healthcare providers, school princi-
pals, local healthcare workers and parents will be offered
to understand and establish initiatives to win the conﬁ-
dence of the communities. A written informed consent
form of the principal of each of the selected schools will
be obtained. Schoolchildren of parents that do not
actively withdraw consent for screening will be examined.
Inclusion criteria for the observational survey will be as
follows: (1) age 5e15 years, (2) written informed consent
for participation in the screening study by the school
principal and (3) passive consent from the parent/
primary care giver of the children. Given the observa-
tional design of the study, no formal exclusion criteria
apply. Children will be enrolled in the prospective
registry in the presence of a documented history of ARF
or echocardiographic evidence of deﬁnite or borderline
RHD and written informed consent given by the children
and/or their parents/primary care givers.
Data collection
A questionnaire customised to the age of the children
will acquire data on social background and past medical
history in a standardised interview. Demographic vari-
ables such as age, household characteristics and socio-
economic indicators will be recorded along with a short
medical history followed by physical examination docu-
menting height, weight and potential clinical signs of
ARF. Screening for RHD will be performed indepen-
dently by cardiac auscultation to detect pathologic heart
murmurs, as well as by echocardiography to document
morphologic and/or functional valvular lesions consis-
tent with RHD. All data will be recorded in a dedicated
web-based database.
Treatment
All patients enrolled in the RHD cohort will be treated
with a standard antibiotic regimen for secondary
prevention consisting of intramuscular administration of
weight-adjusted penicillin G benzathine every 3e4w e e k s
or daily oral administration of penicillin V for the entire
duration of follow-up. Patients allergic to penicillin will be
treated with daily oral administration of azithromycin.
16
Deﬁnitions
ARF will be deﬁned by the modiﬁed Jones criteria.
17
Echocardiographic diagnosis will classify RHD according
to the World Heart Federation criteria for individuals
aged #20 years into deﬁnite and borderline. Deﬁnite
RHD is further subdivided into four subcategories.
Subcategory A is pathological mitral regurgitation and at
least two morphological features of RHD of the mitral
valve and subcategory B is the presence of mitral stenosis
with a mean gradient of $4 mm Hg. Subcategory C is
deﬁned by pathological aortic regurgitation in combina-
tion with at least two morphological features of RHD of
the aortic valve and subcategory D is determined by
borderline disease of both the aortic valve and the mitral
valve. Borderline RHD is subdivided into three subcate-
gories. Subcategory A is the presence of at least two
morphological features of RHD of the mitral valve without
pathological mitral regurgitation or mitral stenosis and
subcategories B and C are determined by pathological
mitral regurgitation or pathological aortic regurgitation,
respectively. Physiological mitral regurgitation (A), physi-
ological aortic regurgitation (B) and an isolated
morphological feature of RHD of the mitral or aortic valve
(ie, valvular thickening) without any associated patholog-
ical stenosis or regurgitation (C and D, respectively) will
be classiﬁed as normal echocardiographic ﬁndings.
13
A patient will be deﬁned as adherent to secondary
prevention if he/she receives at least 80% of the
prescribed intramuscular antibiotic administration
captured from hospital records. In patients receiving
oral antibiotics, adherence will be assessed by self-report
and by pill counts at every follow-up visit. Other treat-
ment adherence end points will be frequency of follow-
up appointments and follow-up status.
Quality of life (QOL) will be assessed using PedsQL
generic core and cardiac module scales. PedsQL
addresses the child’s perspectives across the widest
possible age range. The generic module scale encompass
physical functioning (eight items), emotional func-
tioning (ﬁve items), social functioning (ﬁve items) and
school functioning (ﬁve items). The PedsQL cardiac
module has ﬁve scales related to symptoms (seven
items), perceived physical appearance (three items),
treatment anxiety (four items), cognitive problems (ﬁve
items) and communication (three items).
18
Outcomes and treatment effect
Clinical outcomes such as all-cause mortality, stroke,
endocarditis, hospitalisation for congestive heart failure,
valvular surgery, mitral balloon valvuloplasty and recur-
rence of rheumatic fever will be recorded among
patients with RHD enrolled in the longitudinal cohort
study. Additionally, we will obtain time-varying covariates
like socioeconomic parameters, adherence to treatment
and information on QOL.
We anticipate that compliance with secondary
prevention will be one of the major challenges, which in
turn requires continued education. We plan to ensure
compliance by means of face-to-face education by the
research coordinator at each visit to both the child and
the care giver, making them aware of the risk of
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quences of progression of RHD. Visit reminders by mail
and if necessary by personal visits will also be used to
ensure adequate compliance.
Primary care givers will be educated to detect symp-
toms and signs of potential allergic reactions of antibi-
otic treatment such as a skin rash, hives, swollen lips/
tongue and wheezing and will be provided with an
emergency medical contact number. In case of drug-
related adverse side effects such as diarrhoea, nausea,
pain/swelling/infection at the site of injection, we will
recommend to switch the antibiotic administration from
intramuscular to oral or vice versa as a ﬁrst step. If
children/care givers refuse regular antibiotic intake
despite counselling, they will have the option to retract
their decision at any given point in time. With their
consent, these children will remain in the registry in
order to provide care and treatment in case of potential
late complications as a consequence of disease progres-
sion. In the event of children being diagnosed at an
advanced stage with signiﬁcant valvular heart disease
leading to congestive heart failure, we will assure optimal
interdisciplinary medical treatment.
Quality assurance
All data will be checked for completeness and plausibility
before being entered into a web-based data entry system.
Positive screening results will be veriﬁed in the cardi-
ology outpatient clinic of BPKIHS by complete echo-
cardiographic examination. Quality assurance of the
data will be ensured in a two-tiered fashion. First of all,
the web-based data entry system will not allow for
entering implausible values and text ﬁelds will be
minimal and restricted to speciﬁcation of ‘other’. The
second tier will be automated monthly reports which
generates denominator along with the total frequencies.
When missing data are identiﬁed, the research coordi-
nator will identify the ﬁeld by means of querying and will
try to obtain the values from records or if necessary back
to the participant within 1 month of last contact. The
database will be backed up every week for further secu-
rity on to a dedicated data server. Biannual reports will
be submitted to the foundation ‘Coeur de la Tour’ in
Geneva, Switzerland. The study will be conducted in
compliance with the Declaration of Helsinki.
The study was registered with ClinicalTrials.gov
(NCT01550068) and was given an exempt status by the
ethics committee at University of Bern, Switzerland
(KEK-BE 018/12). The study protocol has been
submitted to the National Nepal Health Research
Council. The study is supported by an unrestricted grant
from the foundation ‘Coeur de la Tour’ (http://www.
coeurdelatour.ch) from Geneva, Switzerland.
Statistical considerations
Sample size
Sample size calculations were based on reported preva-
lence rates of RHD using cardiac auscultation in
schoolchildren in Southeast Asian countries.
4e11 We
calculated a sample size of 9500 schoolchildren between
the ages of 5 and 15 years with a type I error of 0.05 and
a power of 90% for an expected diagnosis rate of 2 per
1000. The lower end of the prevalence estimates was
chosen in order to obtain a sufﬁcient sample size in the
subsequent cohort study and to be able to provide
optimal treatment to a maximum number of affected
children. We will include one urban and three rural
areas from the different parts of the target area (Sunsari
district), thus including 2500 participants in each area.
One-third of the patients from the urban area will be
enrolled from private schools.
Data analysis plan
In the cross-sectional study, age- and sex-speciﬁc preva-
lence rates for RHD will be calculated by sociodemo-
graphic covariates. The design effect of the cluster
sampling strategy will then be calculated using the vari-
ations of prevalence rates among the different clusters.
19
A multiplication factor equal to the square root of the
design effect will be used to construct the 95% CIs for the
prevalence estimates to avoid erroneously narrow CIs.
Prevalence rates with 95% CI will be calculated separately
for the two screening methods. Multivariable analysis will
be performed for assessing the socioeconomic factors for
RHD. Among children with RHD, the socioeconomic
barriers to receive adequate medical care will be assessed
by using a multivariate logistic regression model.
Furthermore, the association of RHD with age, gender,
socioeconomic status and urbanerural residence will be
evaluated with univariate and multivariate analyses.
Cohort baseline characteristics and procedural vari-
ables will be presented as counts and percentages for
dichotomous variables and as mean and SD for contin-
uous variables. Factor analysis of the scales in QOL will be
performed using appropriate rotations, and index scores
of the constructs will be computed if not more than 25%
of the items are missing. Adherence to treatment will be
measured as a dichotomous variable and QOL scores as
mean (SD)/median (IQR) will be presented for each
follow-up time interval. We will present and compare the
baseline and procedural characteristics by the stages of
disease progression at baseline using c
2 tests or analyses
of variance. Comparisons of the baseline characteristics
of the study subjects among the disease stages at baseline
will be performed using linear or logistic regression. For
the speciﬁc clinical end point, compliance and QOL
univariable and multivariable Cox proportional hazard
regression models will be used to calculate HRs with 95%
CI among the stages of disease at baseline. We will
construct KaplaneMeier curves for the time to the
development of clinical end point by stage of disease at
baseline, treating death as a competing risk.
DISCUSSION
This protocol outlines the rationale and design for
a multiphase study including a cross-sectional survey
comparing two different screening methods for RHD
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study addressing the impact of early implementation of
secondary prevention.
The net primary school attendance rate in Nepal
amounts to 86% and 82% for boys and girls, respec-
tively.
15 This study assesses the prevalence of RHD only
to children of families who can afford education, thus
pointing out selection bias. Since access to education is
a marker of socioeconomic status which at the same time
represents a major determinant of susceptibility to ARF
and RHD, restriction of screening to school going chil-
dren is therefore likely to underestimate the real disease
burden related to RHD.
We anticipate certain challenges during the course of
the study. Primarily, screening per se might expose the
children and their families to anxiety related to potential
positive screening results requiring long-term medical
management. Additionally, we acknowledge the social
stigma of being diagnosed with a heart disease especially
among girls in these communities. An information letter
distributed to the parents prior to screening, focus
group discussions and education programmes will
condense clear and simple messages to allay fears
regarding RHD and its subsequent management.
Adequate knowledge and cultural sensitivity not to
offend or harm the children and the parents’ perception
will be of prime importance and will be adhered to
during the entire course of the project.
Even though the population attributable risk of RHD
is expected to be high, false-positive screening results
may occur. In order to reduce false-positive ﬁndings, all
echocardiographic clips with borderline or deﬁnite RHD
will be assessed from two independent cardiologists.
Moreover, screening in a large population of school-
children might yield in exceptional cases important
incidental clinical ﬁndings unrelated to RHD but yet
relevant for future prognosis (ie, bicuspid aortic valve,
atrial septal defect). Parents will be informed about such
ﬁndings and advised on how to proceed for best medical
management. If the parents or caretakers give their
consent, the children will be invited for follow-up at
BPKIHS for further investigation. First medical contact
due to incidental ﬁndings relevant for future prognosis
will be reimbursed.
Prospective clinical studies investigating the impact of
secondary prevention for subclinical RHD on long-term
clinical outcome will be of central relevance for future
health resource utilisation in developing countries.
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